Use of miR-221 and 222 lowering agents to prevent cardiovascular disease in diabetic subjects
US9522130B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Inventor
Key dates
| Filing date | Mar 13, 2014 |
| Grant date | Dec 20, 2016 |
| Priority date | — |
| Expiry date | Mar 13, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methodology for preventing increased cardiovascular disease in subjects with diabetes mellitus. The methods include the use of compounds to inhibit activation of the extracellular response kinase pathway, activate 5′ adenosine monophosphate protein kinase, and inhibit microRNA-221 and microRNA-222 for the purpose of reducing microRNA-221 and -222 levels in the vasculature. Reduction of microRNA-221 and -222 in the vasculature of diabetic patients restores normal levels of intimal thickening and enhances the effectiveness of the standard of care in diabetic subjects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.